staphylococcus aureus neutral proteinase
Biologicalexperimental
Aureolysin is an extracellular metalloprotease expressed by Staphylococcus aureus. This protease is a major contributor to the bacterium's virulence, or ability to cause disease, by cleaving host factors of the innate immune system as well as regulating S. aureus secreted toxins and cell wall proteins. To catalyze its enzymatic activities, aureolysin requires zinc and calcium which it obtains from the extracellular environment within the host. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02301910)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAureolysin ↗
Also known as
- aur protein, staphylococcus aureus
- basic amino acid specific oligoendopeptidase
- protease ii
- protease ii, e coli
- ptrb protein, e coli
- ptrii protein, e coli
- sakstar
- staph aureus protease
- staphylococcal protease
- staphylococcus aureus neutral proteinase
- staphylokinase
- staphylokinase
- tlp protein, e coli
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02301910 | Phase 3 | Oct 1, 2014 | Institute of Cardiology, Tomsk, Russia, Supergene, LLC |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institute of Cardiology, Tomsk, Russia | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Supergene, LLC | For profit | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1